Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Eye cancer, intraocular melanoma
Stage/Subtype:  ciliary body and choroid melanoma, small size
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-12 of 12 for your search:
Start Over
Ipilimumab for Uveal Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0919, NCI-2012-00665, NCT01585194
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1312169092, NCT02065466
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 17780, NCT02385669
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 17860, NCT02425306
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10D.95, NCT01473004
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BMS CA184-168, NCT01565837
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: 130093, 13-C-0093, NCT01814046
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-02091, 13-144, 9445, N01CM00039, P30CA008748, NCT01979523
Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13P.377, 2013-047, NCT02068586
CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00898, CITN-07-FLT3L, U01CA154967, NCT02129075
Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-063, NCT02223819
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Phase: Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 07-0652 / 201103308, NCT00683670
Start Over